REPLICA-EPICA 18 Registry: Using IVL in Calcified Coronary Lesions

The presence of calcification in the coronary arteries (CAC) remains the main challenge in the percutaneous treatment of these lesions. Various studies have demonstrated the association of CAC with unfavorable long-term outcomes. Intravascular lithotripsy (IVL) has emerged as an effective tool for fracturing calcified plaques. Studies evaluating this strategy have shown high device success rates, with good clinical and angiographic outcomes. These, however, have not been randomized trials.

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

The aim of this prospective, multicenter study was to assess the effectiveness and safety of IVL in calcified lesions in a cohort of consecutive real-world patients.

The primary efficacy endpoint (PEP) was procedural success, defined as successful percutaneous coronary intervention (PCI) with residual stenosis <20% and no in-hospital complications (cardiac death, acute myocardial infarction [AMI], or need for target vessel revascularization [TVR]). The secondary safety endpoint (SEP) was the rate of major adverse cardiac events (MACE), defined as death, AMI, or TVR.

The study included a total of 426 patients with 456 lesions. The mean age was 73 years, and most patients were men. The most frequent clinical presentation was acute coronary syndrome (ACS), in 63% of cases. Most patients had good ventricular function (LVEF >50%), and transradial access was the most frequently used access (76%). The most affected coronary artery was the left anterior descending artery (44%), followed by the right coronary artery (31%), the circumflex artery (12%), and the left main coronary artery (11%).

Read also: Third Generation Balloon-Expandable and Self-Expanding Valves: TAVR Meta- Analysis.

Regarding the efficacy PEP, it was achieved in 66% of the patients, with similar rates between ACS patients (65%) and patients with chronic coronary syndromes (CCS) (68%). There were no significant differences in angiographic success after IVL between these two patient groups. As for the safety SEP, the 30-day MACE rate was 3%: it was 1% in CCS patients and 5% in ACS patients (p=0.073).

Conclusion

The use of IVL proved to be a feasible and safe procedure in a real-world patient population, effectively facilitating stent implantation in severely calcified lesions. ACS patients showed similar angiographic success rates but tended to have higher 30-day MACE rates compared with CCS patients. Long-term studies are needed to evaluate the clinical benefits associated with this therapeutic tool.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: A Prospective, Multicenter, Real-World Registry of Coronary Lithotripsy in Calcified Coronary Arteries The REPLICA-EPIC18 Study.

Reference: Oriol Rodriguez-Leor, MD, PHD et al J Am Coll Cardiol Intv 2024.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...